Buy Glenmark Pharma, target price Rs 390: ICICI Securities

Overall, revenue and EPS CAGRs of 8.8% and 16.4% respectively are expected over FY20-FY22E with the core margin rising 100 bps to 17%.

 
– Stocks-Markets-Economic Times

• Share on Facebook
• Tweet it
• Pin it
• Share it
• Email